Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-shot CAR-T therapy takes on stem cell transplant for multiple myeloma

NCT ID NCT07735637

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a single infusion of AZD0120, a CAR-T cell therapy that targets two proteins on myeloma cells, can outperform the standard approach of high-dose chemotherapy followed by a stem cell transplant. The study enrolls adults newly diagnosed with multiple myeloma who have already completed initial treatment. Researchers will compare how long the cancer stays under control and whether the CAR-T approach leads to deeper remissions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental dual-targeting CAR-T cell therapy called AZD0120, which targets two proteins (BCMA and CD19) on myeloma cells
What this could lead to
If successful, this could offer a less intensive, one-time treatment alternative to stem cell transplant for newly diagnosed multiple myeloma, potentially improving long-term remission rates.
What could go wrong
This is an early-phase trial comparing a new therapy to a standard procedure. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological issues, and it is not yet proven to be better than stem cell transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

Contacts and locations

Locations

  • Research Site

    Tampa, Florida, 33612, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Atlanta, Georgia, 30342, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Detroit, Michigan, 48201, United States

  • Research Site

    Rochester, Minnesota, 55905, United States

  • Research Site

    Cleveland, Ohio, 44195, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    Seattle, Washington, 98104, United States

  • Research Site

    Milwaukee, Wisconsin, 53226, United States

  • Research Site

    Brisbane, 4102, Australia

  • Research Site

    Camperdown, 2050, Australia

  • Research Site

    Darlinghurst, 2010, Australia

  • Research Site

    Fitzroy, VIC3065, Australia

  • Research Site

    Melbourne, 3004, Australia

  • Research Site

    Nedlands, 6009, Australia

  • Research Site

    Salvador, 41253-190, Brazil

  • Research Site

    São Paulo, 01509-900, Brazil

  • Research Site

    São Paulo, 05652-900, Brazil

  • Research Site

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    Aarhus, 8200, Denmark

  • Research Site

    København Ø, 2100, Denmark

  • Research Site

    Odense, 5464, Denmark

  • Research Site

    Lille, 59037, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75012, France

  • Research Site

    Paris, 75475, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Berlin, 10117, Germany

  • Research Site

    Dresden, 01307, Germany

  • Research Site

    Essen, 45122, Germany

  • Research Site

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Leipzig, 04103, Germany

  • Research Site

    München, 81675, Germany

  • Research Site

    Oldenburg, 26133, Germany

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Milan, 20133, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Rome, 00168, Italy

  • Research Site

    Rozzano, 20089, Italy

  • Research Site

    Torino, 10100, Italy

  • Research Site

    Oslo, 0450, Norway

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Gliwice, 44-100, Poland

  • Research Site

    Kielce, 25-734, Poland

  • Research Site

    Krakow, 30-688, Poland

  • Research Site

    Lublin, 20-090, Poland

  • Research Site

    Wroclaw, 50-556, Poland

  • Research Site

    Singapore, 119228, Singapore

  • Research Site

    Singapore, 169608, Singapore

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Seoul, 5505, South Korea

  • Research Site

    Badalona, 08916, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    El Palmar, 30120, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Santander, 39008, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Taipei, 106, Taiwan

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.